NAD + in fatty liver disease: mechanistic insights and associated targets
Cell Biology and Toxicology · 26.11.2025 · 41 (1)
DOI: 10.1007/s10565-025-10106-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell Biology and Toxicology, online erschienen am 26.11.2025. Verfasst von Yaxin Guo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Hospital of China Medical University, Shenyang, 110801, China. Hauptthemen laut MEDLINE: NAD, Fatty Liver. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 225 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Fatty liver disease, encompassing metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD), is frequently linked to high-calorie diets, excessive alcohol consumption, or other metabolic disorders. These conditions can escalate to cirrhosis and even hepatocellular cancer (HCC), resulting in a substantial economic burden worldwide. Nicotinamide adenine dinucleotide (NAD +) is a coenzyme that plays a critical role in cellular metabolism and homeostasis. Its depletion has been observed in cases of fatty liver disease, while restoration of NAD + levels has been shown to mitigate the initiation and progression of disease. This review presents advances of NAD + in the pathophysiology of fatty liver disease, focusing on the biological roles of NAD + in liver lipid accumulation, oxidative stress, endoplasmic reticulum stress (ERS), inflammation, autophagy, and liver fibrosis during the development of fatty liver disease. Furthermore, the potential of NAD + as a therapeutic target for fatty liver disease is also discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, The First Hospital of China Medical University, Shenyang, 110801, China.
- Department of General Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, 110032, China.
- Department of General Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, 110032, China. wangyong@cmu.edu.cn.
- Department of General Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, 110032, China. liuxinde@cmu.edu.cn.
Zitieren
APA
Guo, Y., Wang, Y., Wu, S., Wang, Y., & Liu, X. (2025). NAD + in fatty liver disease: mechanistic insights and associated targets. Cell Biology and Toxicology, 41(1). https://doi.org/10.1007/s10565-025-10106-7
Vancouver
Guo Y, Wang Y, Wu S, Wang Y, Liu X. NAD + in fatty liver disease: mechanistic insights and associated targets. Cell Biology and Toxicology. 2025;41(1). doi:10.1007/s10565-025-10106-7
BibTeX
@article{Guo2025,
author = {Guo, Yaxin and Wang, Yuting and Wu, Shiran and Wang, Yong and Liu, Xinde},
title = {NAD + in fatty liver disease: mechanistic insights and associated targets},
journal = {Cell Biology and Toxicology},
year = {2025},
volume = {41},
number = {1},
doi = {10.1007/s10565-025-10106-7}
}
EUVIMED